Brexit – Indian Pharma’s Diversified Play A Buffer?
This article was originally published in PharmAsia News
Indian markets slumped on June 24 after the UK voted to exit the EU, though industry experts had mixed views on how things may pan out for Indian drug firms with an exposure in Britain or Europe as a whole. Most concurred only that there would be turbulence in the currency markets in the short term.
You may also be interested in...
India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.